TG Therapeutics, Inc. (TGTX)
USD 34.75
(-6.96%)
USD 34.75
(-6.96%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 12.67 Million USD | 106.22% |
| 2022 | -203.83 Million USD | 42.67% |
| 2021 | -355.55 Million USD | -24.37% |
| 2020 | -285.87 Million USD | -59.4% |
| 2019 | -179.34 Million USD | -3.38% |
| 2018 | -173.48 Million USD | -46.43% |
| 2017 | -118.47 Million USD | -51.4% |
| 2016 | -78.25 Million USD | -24.31% |
| 2015 | -62.94 Million USD | -12.85% |
| 2014 | -55.78 Million USD | -172.39% |
| 2013 | -20.47 Million USD | -13.31% |
| 2012 | -18.07 Million USD | -2018.54% |
| 2011 | -853.07 Thousand USD | -236.79% |
| 2010 | 623.64 Thousand USD | 122.33% |
| 2009 | -2.79 Million USD | 34.57% |
| 2008 | -4.26 Million USD | 64.52% |
| 2007 | -12.03 Million USD | -24.11% |
| 2006 | -9.69 Million USD | 49.35% |
| 2005 | -19.14 Million USD | -224.64% |
| 2004 | -5.89 Million USD | 1.09% |
| 2003 | -5.96 Million USD | -285.34% |
| 2002 | -1.54 Million USD | 10.84% |
| 2001 | -1.73 Million USD | 70.1% |
| 2000 | -5.8 Million USD | -141.77% |
| 1999 | -2.4 Million USD | 14.29% |
| 1998 | -2.8 Million USD | 46.15% |
| 1997 | -5.2 Million USD | -44.44% |
| 1996 | -3.6 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 6.87 Million USD | 164.25% |
| 2024 Q3 | 3.88 Million USD | -43.6% |
| 2024 Q1 | -10.7 Million USD | 25.73% |
| 2023 Q1 | -38.62 Million USD | 28.37% |
| 2023 Q3 | 113.93 Million USD | 339.3% |
| 2023 Q4 | -14.41 Million USD | -112.65% |
| 2023 FY | 12.67 Million USD | 106.22% |
| 2023 Q2 | -47.61 Million USD | -23.25% |
| 2022 FY | -203.83 Million USD | 42.67% |
| 2022 Q4 | -53.92 Million USD | -47.04% |
| 2022 Q1 | -71.15 Million USD | 23.77% |
| 2022 Q2 | -42.07 Million USD | 40.86% |
| 2022 Q3 | -36.67 Million USD | 12.85% |
| 2021 Q1 | -90.62 Million USD | -2.73% |
| 2021 Q2 | -78.49 Million USD | 13.39% |
| 2021 Q4 | -93.33 Million USD | -8.99% |
| 2021 Q3 | -85.63 Million USD | -9.1% |
| 2021 FY | -355.55 Million USD | -24.37% |
| 2020 Q3 | -87.16 Million USD | -64.82% |
| 2020 Q1 | -51.11 Million USD | -29.18% |
| 2020 Q2 | -52.88 Million USD | -3.46% |
| 2020 Q4 | -88.21 Million USD | -1.21% |
| 2020 FY | -285.87 Million USD | -59.4% |
| 2019 FY | -179.34 Million USD | -3.38% |
| 2019 Q4 | -39.57 Million USD | 36.1% |
| 2019 Q3 | -61.93 Million USD | -71.02% |
| 2019 Q2 | -36.21 Million USD | -3.01% |
| 2019 Q1 | -35.15 Million USD | 34.73% |
| 2018 FY | -173.48 Million USD | -46.43% |
| 2018 Q3 | -33.95 Million USD | 23.09% |
| 2018 Q2 | -44.14 Million USD | -6.29% |
| 2018 Q1 | -41.52 Million USD | -34.57% |
| 2018 Q4 | -53.86 Million USD | -58.64% |
| 2017 Q4 | -30.85 Million USD | 2.14% |
| 2017 FY | -118.47 Million USD | -51.4% |
| 2017 Q1 | -27.72 Million USD | -17.12% |
| 2017 Q2 | -28.35 Million USD | -2.26% |
| 2017 Q3 | -31.53 Million USD | -11.22% |
| 2016 Q1 | -13.84 Million USD | 21.37% |
| 2016 Q2 | -15.89 Million USD | -14.81% |
| 2016 FY | -78.25 Million USD | -24.31% |
| 2016 Q3 | -24.83 Million USD | -56.18% |
| 2016 Q4 | -23.67 Million USD | 4.66% |
| 2015 Q3 | -13.65 Million USD | 20.16% |
| 2015 Q1 | -14.57 Million USD | 22.44% |
| 2015 Q2 | -17.1 Million USD | -17.32% |
| 2015 Q4 | -17.61 Million USD | -28.97% |
| 2015 FY | -62.94 Million USD | -12.85% |
| 2014 Q2 | -11.98 Million USD | -58.82% |
| 2014 Q3 | -17.45 Million USD | -45.59% |
| 2014 Q4 | -18.79 Million USD | -7.71% |
| 2014 FY | -55.78 Million USD | -172.39% |
| 2014 Q1 | -7.54 Million USD | -33.25% |
| 2013 Q4 | -5.66 Million USD | -24.31% |
| 2013 Q1 | -3.67 Million USD | -6.18% |
| 2013 Q2 | -6.58 Million USD | -79.24% |
| 2013 Q3 | -4.55 Million USD | 30.8% |
| 2013 FY | -20.47 Million USD | -13.31% |
| 2012 Q1 | -10.25 Million USD | -790.92% |
| 2012 Q4 | -3.45 Million USD | -40.51% |
| 2012 Q3 | -2.46 Million USD | -29.96% |
| 2012 Q2 | -1.89 Million USD | 81.53% |
| 2012 FY | -18.07 Million USD | -2018.54% |
| 2011 Q1 | 3.83 Million USD | 949.3% |
| 2011 FY | -853.07 Thousand USD | -236.79% |
| 2011 Q4 | -1.15 Million USD | -108.65% |
| 2011 Q2 | -2.98 Million USD | -177.82% |
| 2011 Q3 | -551.73 Thousand USD | 81.5% |
| 2010 Q4 | 365.23 Thousand USD | 785.47% |
| 2010 FY | 623.64 Thousand USD | 122.33% |
| 2010 Q2 | 1.85 Million USD | 213.3% |
| 2010 Q1 | -1.63 Million USD | -632.65% |
| 2010 Q3 | 41.24 Thousand USD | -97.77% |
| 2009 Q1 | -761.84 Thousand USD | -699.79% |
| 2009 Q2 | -1.39 Million USD | -82.77% |
| 2009 Q4 | -222.91 Thousand USD | 46.43% |
| 2009 Q3 | -416.08 Thousand USD | 70.12% |
| 2009 FY | -2.79 Million USD | 34.57% |
| 2008 Q2 | -1.42 Million USD | 8.8% |
| 2008 Q3 | -1.39 Million USD | 1.96% |
| 2008 FY | -4.26 Million USD | 64.52% |
| 2008 Q4 | 127.01 Thousand USD | 109.11% |
| 2008 Q1 | -1.55 Million USD | 18.1% |
| 2007 Q4 | -1.9 Million USD | 28.67% |
| 2007 Q1 | -2.56 Million USD | 18.03% |
| 2007 Q2 | -4.89 Million USD | -90.87% |
| 2007 Q3 | -2.66 Million USD | 45.46% |
| 2007 FY | -12.03 Million USD | -24.11% |
| 2006 Q1 | -2.81 Million USD | -10.77% |
| 2006 Q4 | -3.12 Million USD | -64.88% |
| 2006 FY | -9.69 Million USD | 49.35% |
| 2006 Q2 | -2.27 Million USD | 19.32% |
| 2006 Q3 | -1.89 Million USD | 16.45% |
| 2005 Q1 | -1.42 Million USD | 18.28% |
| 2005 Q2 | -13.36 Million USD | -836.91% |
| 2005 Q3 | -1.81 Million USD | 86.43% |
| 2005 Q4 | -2.54 Million USD | -40.21% |
| 2005 FY | -19.14 Million USD | -224.64% |
| 2004 Q2 | -861.6 Thousand USD | 21.34% |
| 2004 Q1 | -1.09 Million USD | 27.44% |
| 2004 FY | -5.89 Million USD | 1.09% |
| 2004 Q4 | -1.74 Million USD | 20.47% |
| 2004 Q3 | -2.19 Million USD | -154.65% |
| 2003 Q4 | -1.5 Million USD | 53.59% |
| 2003 Q1 | -421.94 Thousand USD | -13.83% |
| 2003 FY | -5.96 Million USD | -285.34% |
| 2003 Q3 | -3.25 Million USD | -319.03% |
| 2003 Q2 | -776.31 Thousand USD | -83.99% |
| 2002 Q4 | -370.68 Thousand USD | 36.79% |
| 2002 FY | -1.54 Million USD | 10.84% |
| 2002 Q3 | -586.41 Thousand USD | -1812.96% |
| 2002 Q2 | 34.23 Thousand USD | 105.49% |
| 2002 Q1 | -624.07 Thousand USD | -10.43% |
| 2001 Q2 | -2.12 Million USD | -225.74% |
| 2001 Q3 | -735.56 Thousand USD | 65.32% |
| 2001 Q4 | -565.15 Thousand USD | 23.17% |
| 2001 FY | -1.73 Million USD | 70.1% |
| 2001 Q1 | 1.68 Million USD | 562.86% |
| 2000 Q1 | -1.37 Million USD | -129.71% |
| 2000 Q4 | -364.45 Thousand USD | 62.52% |
| 2000 Q2 | -3.08 Million USD | -124.01% |
| 2000 Q3 | -972.42 Thousand USD | 68.5% |
| 2000 FY | -5.8 Million USD | -141.77% |
| 1999 Q3 | -300 Thousand USD | 50.0% |
| 1999 FY | -2.4 Million USD | 14.29% |
| 1999 Q4 | -600 Thousand USD | -100.0% |
| 1999 Q1 | -900 Thousand USD | 30.77% |
| 1999 Q2 | -600 Thousand USD | 33.33% |
| 1998 Q3 | -1.2 Million USD | -220.0% |
| 1998 Q1 | -1.3 Million USD | 13.33% |
| 1998 FY | -2.8 Million USD | 46.15% |
| 1998 Q4 | -1.3 Million USD | -8.33% |
| 1998 Q2 | 1 Million USD | 176.92% |
| 1997 Q4 | -1.5 Million USD | -50.0% |
| 1997 FY | -5.2 Million USD | -44.44% |
| 1997 Q2 | -1.8 Million USD | -100.0% |
| 1997 Q1 | -900 Thousand USD | 10.0% |
| 1997 Q3 | -1 Million USD | 44.44% |
| 1996 Q4 | -1 Million USD | 9.09% |
| 1996 FY | -3.6 Million USD | 0.0% |
| 1996 Q3 | -1.1 Million USD | -37.5% |
| 1996 Q2 | -800 Thousand USD | 0.0% |
| 1996 Q1 | -800 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -146.39 Million USD | 108.656% |
| Alkermes plc | 355.75 Million USD | 96.438% |
| Agenus Inc. | -245.76 Million USD | 105.156% |
| Aptorum Group Limited | -2.82 Million USD | 548.622% |
| Ardelyx, Inc. | -66.06 Million USD | 119.181% |
| Dyadic International, Inc. | -6.79 Million USD | 286.477% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | 1453.846% |
| Lantern Pharma Inc. | -15.96 Million USD | 179.391% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 166.594% |
| Novavax, Inc. | -545.06 Million USD | 102.325% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 121.738% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 117.173% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 168.327% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | 226.898% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 121.484% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 103.392% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 152.064% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 133.937% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 107.7% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 117.277% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 162.451% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 120.355% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 139.009% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 109.564% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 102.878% |
| AlloVir, Inc. | -190.41 Million USD | 106.655% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 106.173% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 144.538% |
| Bicycle Therapeutics plc | -180.66 Million USD | 107.014% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 107.077% |
| ChromaDex Corporation | -4.93 Million USD | 356.622% |
| Chimerix, Inc. | -82.09 Million USD | 115.436% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 128.41% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 112.415% |
| CRISPR Therapeutics AG | -153.61 Million USD | 108.249% |
| Precision BioSciences, Inc. | -61.31 Million USD | 120.666% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 107.874% |
| Fortress Biotech, Inc. | -60.63 Million USD | 120.898% |
| Fortress Biotech, Inc. | -60.63 Million USD | 120.898% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 115.533% |
| ImmuCell Corporation | -5.77 Million USD | 319.444% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 111.218% |
| Immix Biopharma, Inc. | -15.42 Million USD | 182.147% |
| Incyte Corporation | 597.59 Million USD | 97.88% |
| Innoviva, Inc. | 179.72 Million USD | 92.949% |
| IO Biotech, Inc. | -86.08 Million USD | 114.721% |
| Jaguar Health, Inc. | -41.3 Million USD | 130.683% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 108.283% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | 75.703% |
| ContextLogic Inc. | -317 Million USD | 103.997% |
| MiMedx Group, Inc. | 67.43 Million USD | 81.21% |
| MEI Pharma, Inc. | 17.77 Million USD | 28.721% |
| NextCure, Inc. | -62.72 Million USD | 120.203% |
| Onconetix, Inc. | -37.4 Million USD | 133.874% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 132.098% |
| Opthea Limited | -220.24 Million USD | 105.754% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 124.77% |
| Vaxcyte, Inc. | -402.26 Million USD | 103.15% |
| PDS Biotechnology Corporation | -42.94 Million USD | 129.509% |
| Precigen, Inc. | -95.9 Million USD | 113.213% |
| Pharming Group N.V. | -10.54 Million USD | 220.137% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 106.286% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 151.632% |
| PureTech Health plc | -65.69 Million USD | 119.289% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 150.504% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 105.971% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 152.064% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 104.915% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 146.523% |
| Acelyrin, Inc. | -381.64 Million USD | 103.32% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | 101130.959% |
| Summit Therapeutics Inc. | -614.92 Million USD | 102.061% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 137.16% |
| Senti Biosciences, Inc. | -92.91 Million USD | 113.638% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 112.103% |
| Elevation Oncology, Inc. | -45.7 Million USD | 127.726% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 136.061% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | 196.941% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | 289.559% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 143.158% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 249.065% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 122.033% |
| Seer, Inc. | -86.27 Million USD | 114.688% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 118.915% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 119.269% |
| ESSA Pharma Inc. | -26.58 Million USD | 147.671% |
| GlycoMimetics, Inc. | -36.89 Million USD | 134.342% |
| GT Biopharma, Inc. | -7.59 Million USD | 266.803% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 105.25% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | 124.404% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | 82.255% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 123.285% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 125.798% |
| Alzamend Neuro, Inc. | -9.94 Million USD | 227.386% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 102.212% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | 453.177% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 124.819% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 105.16% |
| Aptose Biosciences Inc. | -51.2 Million USD | 124.747% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 112.891% |
| Soligenix, Inc. | -6.14 Million USD | 306.36% |
| Century Therapeutics, Inc. | -136.67 Million USD | 109.272% |
| Kura Oncology, Inc. | -152.63 Million USD | 108.302% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 114.203% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | 220.251% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | -2140.968% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | 2327.065% |
| Autolus Therapeutics plc | -208.38 Million USD | 106.081% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 117.625% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 117.9% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 158.483% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 105.626% |
| GRI Bio, Inc. | -13.03 Million USD | 197.2% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | 406.488% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 110.212% |
| IGM Biosciences, Inc. | -246.41 Million USD | 105.143% |
| INmune Bio, Inc. | -30 Million USD | 142.229% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 111.462% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 130.033% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 179.39% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 180.228% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 121.231% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 112.526% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 104.589% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 105.327% |
| Verastem, Inc. | -87.36 Million USD | 114.504% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 123.385% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 107.854% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 110.863% |
| Histogen Inc. | -10.62 Million USD | 219.311% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 188.698% |
| Surrozen, Inc. | -43.04 Million USD | 129.441% |
| Organovo Holdings, Inc. | -14.67 Million USD | 186.374% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 349.104% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 124.211% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 150.16% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 147.041% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | 251.632% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 108.387% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 125.9% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 142.631% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | 221.639% |
| Apollomics, Inc. | -172.6 Million USD | 107.342% |
| Amarin Corporation plc | -59.11 Million USD | 121.437% |
| Mesoblast Limited | -87.95 Million USD | 114.407% |
| Turnstone Biologics Corp. | -55.2 Million USD | 122.957% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 108.623% |
| Synaptogenix, Inc. | -6.03 Million USD | 309.853% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 178.184% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 116.242% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 364.47% |
| Monopar Therapeutics Inc. | -8.4 Million USD | 250.818% |
| Exelixis, Inc. | 207.76 Million USD | 93.901% |
| Better Therapeutics, Inc. | -39.76 Million USD | 131.871% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 108.803% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 102.397% |
| NLS Pharmaceutics AG | -12.17 Million USD | 204.108% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | 262.572% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 141.211% |
| Gritstone bio, Inc. | -138.49 Million USD | 109.15% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 119.657% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 416.804% |
| Avid Bioservices, Inc. | -140.75 Million USD | 109.003% |
| Insmed Incorporated | -749.56 Million USD | 101.691% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 183.426% |
| MediWound Ltd. | -6.71 Million USD | 288.684% |
| OmniAb, Inc. | -50.61 Million USD | 125.034% |
| Alector, Inc. | -130.39 Million USD | 109.718% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 111.143% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 124.441% |
| Zai Lab Limited | -334.62 Million USD | 103.787% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 103.911% |
| Aura Biosciences, Inc. | -76.4 Million USD | 116.585% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 105.401% |
| Immunic, Inc. | -93.61 Million USD | 113.537% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 109.325% |
| Veracyte, Inc. | -74.4 Million USD | 117.031% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | 265.096% |
| FibroGen, Inc. | -284.23 Million USD | 104.458% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 148.307% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 280.98% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 167.287% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 96.945% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 156.183% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | 74.281% |
| Galecto, Inc. | -38.34 Million USD | 133.044% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 167.168% |
| Fortrea Holdings Inc. | -3.4 Million USD | 472.706% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 110.006% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 172.782% |
| XBiotech Inc. | -24.55 Million USD | 151.602% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 119.657% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 120.217% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 112.875% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 159.14% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 122.959% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 102.089% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 118.566% |
| Vaxxinity, Inc. | -56.93 Thousand USD | 22357.351% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 105.594% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 156.908% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 105.768% |
| NexImmune, Inc. | -32.34 Million USD | 139.178% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | 339.702% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 190.219% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 99.679% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 152.318% |
| Scopus BioPharma Inc. | -11.6 Million USD | 209.149% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 110.85% |
| Ainos, Inc. | -13.77 Million USD | 192.022% |
| Pluri Inc. | -20.88 Million USD | 160.666% |
| Prothena Corporation plc | -147.02 Million USD | 108.619% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 111.128% |
| Celularity Inc. | -196.29 Million USD | 106.456% |
| Rallybio Corporation | -74.56 Million USD | 116.995% |
| Cue Biopharma, Inc. | -50.73 Million USD | 124.978% |
| MeiraGTx Holdings plc | -84.02 Million USD | 115.081% |
| Omeros Corporation | -117.81 Million USD | 110.756% |
| Humacyte, Inc. | -110.77 Million USD | 111.439% |
| Immunocore Holdings plc | -55.28 Million USD | 122.92% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 170.463% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 155.261% |
| Blueprint Medicines Corporation | -506.98 Million USD | 102.499% |
| CalciMedica, Inc. | -34.35 Million USD | 136.883% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 118.725% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 108.961% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 107.643% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 104.474% |
| Pulmatrix, Inc. | -14.12 Million USD | 189.739% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 136.005% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 115.334% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 102.633% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 112.083% |
| Cytokinetics, Incorporated | -526.24 Million USD | 102.408% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 135.137% |
| Nutriband Inc. | -5.48 Million USD | 331.017% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 131.351% |
| Vor Biopharma Inc. | -117.86 Million USD | 110.751% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 99.709% |
| Evogene Ltd. | -23.87 Million USD | 153.068% |
| ProKidney Corp. | -35.46 Million USD | 135.728% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 110.581% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | 261.522% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 101.97% |
| CorMedix Inc. | -46.33 Million USD | 127.346% |
| BioLineRx Ltd. | -60.61 Million USD | 120.906% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 112.455% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 130.858% |
| Atai Life Sciences N.V. | -40.22 Million USD | 131.504% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 115.712% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 116.779% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 104.337% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 145.458% |
| MediciNova, Inc. | -8.57 Million USD | 247.838% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 110.279% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 251.274% |
| GeoVax Labs, Inc. | -25.96 Million USD | 148.801% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 105.297% |
| Biomea Fusion, Inc. | -117.25 Million USD | 110.807% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 102.022% |
| Mereo BioPharma Group plc | -29.46 Million USD | 143.005% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 108.274% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 106.053% |
| Absci Corporation | -110.56 Million USD | 111.461% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 142.03% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 112.567% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 105.371% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | 10.026% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 106.567% |
| Allakos Inc. | -185.7 Million USD | 106.824% |
| Imunon, Inc. | -19.51 Million USD | 164.935% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 113.019% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 88.061% |
| BioAtla, Inc. | -123.46 Million USD | 110.264% |
| NLS Pharmaceutics AG | -12.17 Million USD | 204.108% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 178.816% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 103.872% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 134.296% |
| XOMA Corporation | -40.83 Million USD | 131.035% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 112.439% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 110.692% |
| aTyr Pharma, Inc. | -50.38 Million USD | 125.148% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 114.453% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 108.35% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 105.33% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 136.083% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | 256.6% |
| Akari Therapeutics, Plc | -10 Million USD | 226.619% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 18922.131% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 95.5% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 290.13% |
| UroGen Pharma Ltd. | -102.24 Million USD | 112.394% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 111.866% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 262.938% |
| Orgenesis Inc. | -55.36 Million USD | 122.89% |
| Entera Bio Ltd. | -8.88 Million USD | 242.558% |
| GH Research PLC | -35.58 Million USD | 135.609% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 160.806% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 116.375% |
| Xencor, Inc. | -126.08 Million USD | 110.05% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | 436.511% |
| Replimune Group, Inc. | -215.79 Million USD | 105.872% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 159.587% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | -405.062% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 290.13% |
| Portage Biotech Inc. | -75.33 Million USD | 116.82% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 251.274% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 113.111% |
| OncoCyte Corporation | -27.78 Million USD | 145.614% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | 194.446% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | 213.941% |
| Purple Biotech Ltd. | -19.88 Million USD | 163.742% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | 280.539% |
| scPharmaceuticals Inc. | -54.81 Million USD | 123.12% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 172.386% |
| HilleVax, Inc. | -123.56 Million USD | 110.255% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | 225.378% |
| Tharimmune, Inc. | -9.31 Million USD | 235.979% |
| Genprex, Inc. | -30.86 Million USD | 141.062% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 105.371% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 142.108% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | 811.111% |
| Virios Therapeutics, Inc. | -5.29 Million USD | 339.274% |
| OKYO Pharma Limited | -16.82 Thousand USD | 75414.434% |
| Savara Inc. | -54.69 Million USD | 123.167% |
| Curis, Inc. | -47.41 Million USD | 126.727% |
| Daré Bioscience, Inc. | -30.16 Million USD | 142.014% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 182.046% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | 327.545% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 142.502% |
| BeiGene, Ltd. | -881.7 Million USD | 101.437% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 159.51% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 102.904% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 116.05% |
| Erasca, Inc. | -125.04 Million USD | 110.134% |
| bluebird bio, Inc. | -211.91 Million USD | 105.98% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 353.415% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 92.441% |
| DBV Technologies S.A. | -72.72 Million USD | 117.424% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 353.415% |
| Moderna, Inc. | -4.71 Billion USD | 100.269% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 131.556% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | 322.55% |
| Molecular Templates, Inc. | -8.12 Million USD | 255.982% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 120.984% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 111.375% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 109.362% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 126.445% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 108.96% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 106.586% |
| MacroGenics, Inc. | -9.05 Million USD | 239.898% |
| RenovoRx, Inc. | -10.23 Million USD | 223.847% |
| Adicet Bio, Inc. | -142.65 Million USD | 108.883% |
| Prime Medicine, Inc. | -198.13 Million USD | 106.396% |
| Aditxt, Inc. | -32.38 Million USD | 139.134% |
| Adagene Inc. | -18.94 Million USD | 166.884% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 273.311% |
| Quantum-Si incorporated | -95.96 Million USD | 113.206% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 110.646% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 186.927% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | 90.424% |
| SciSparc Ltd. | -5.12 Million USD | 347.403% |
| Vericel Corporation | -3.18 Million USD | 498.24% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 10637.695% |
| Minerva Neurosciences, Inc. | -30 Million USD | 142.232% |
| Generation Bio Co. | -126.61 Million USD | 110.009% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 117.385% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 115.371% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 104.834% |
| Invivyd, Inc. | -198.64 Million USD | 106.379% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 103.706% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | 245.88% |
| Spero Therapeutics, Inc. | 22.8 Million USD | 44.436% |
| Artelo Biosciences, Inc. | -9.87 Million USD | 228.337% |
| 2seventy bio, Inc. | -217.57 Million USD | 105.824% |
| ADMA Biologics, Inc. | -28.23 Million USD | 144.874% |
| Clene Inc. | -49.5 Million USD | 125.598% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 156.857% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 125.634% |
| GeoVax Labs, Inc. | -25.96 Million USD | 148.801% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 103.863% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 138.939% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | 44.225% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 112.827% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 116.952% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 107.88% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 102.06% |
| Evaxion Biotech A/S | -22.12 Million USD | 157.275% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 115.696% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 106.334% |
| Trevena, Inc. | -40.28 Million USD | 131.453% |
| Surrozen, Inc. | -43.04 Million USD | 129.441% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 118.33% |
| Cingulate Inc. | -23.53 Million USD | 153.843% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | 283.333% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 131.791% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | 264.344% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 114.047% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 120.677% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 121.296% |
| Clearmind Medicine Inc. | -11.95 Million USD | 205.997% |
| Kronos Bio, Inc. | -112.67 Million USD | 111.247% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 118.313% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 499739.228% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 114.753% |
| Statera Biopharma, Inc. | -174.4 Million USD | 107.266% |
| ImmunityBio, Inc. | -583.19 Million USD | 102.173% |
| Korro Bio, Inc. | -81.17 Million USD | 115.611% |
| Kineta, Inc. | -14.09 Million USD | 189.879% |
| BioVie Inc. | -32.12 Million USD | 139.451% |
| Codexis, Inc. | -76.24 Million USD | 116.621% |
| Celularity Inc. | -196.29 Million USD | 106.456% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 105.907% |
| Celcuity Inc. | -63.77 Million USD | 119.869% |
| Virax Biolabs Group Limited | -6.73 Million USD | 288.192% |
| Cibus, Inc. | -267.62 Million USD | 104.735% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 131.424% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 135.386% |
| IN8bio, Inc. | -30 Million USD | 142.23% |
| Kodiak Sciences Inc. | -260.49 Million USD | 104.865% |
| Annexon, Inc. | -134.23 Million USD | 109.44% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 110.816% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 120.696% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 140.172% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 103.46% |
| Eyenovia, Inc. | -27.26 Million USD | 146.484% |
| Puma Biotechnology, Inc. | 21.59 Million USD | 41.309% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 2468.598% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 116.586% |
| Arcellx, Inc. | -70.69 Million USD | 117.926% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 130.578% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 109.47% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 142.188% |
| Moolec Science SA | -51.78 Million USD | 124.469% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 124.197% |
| Geron Corporation | -184.12 Million USD | 106.882% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 130.19% |
| Royalty Pharma plc | 1.13 Billion USD | 98.883% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 109.321% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | 242.513% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 159.652% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 107.382% |
| Humacyte, Inc. | -110.77 Million USD | 111.439% |
| Structure Therapeutics Inc. | -89.62 Million USD | 114.14% |
| 89bio, Inc. | -142.18 Million USD | 108.912% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 118.376% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | 222.116% |
| Genelux Corporation | -28.29 Million USD | 144.782% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 143.599% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 107.155% |
| Notable Labs, Ltd. | -11.26 Million USD | 212.5% |
| Liquidia Corporation | -78.5 Million USD | 116.142% |
| Mustang Bio, Inc. | -51.6 Million USD | 124.557% |
| Immunovant, Inc. | -259.33 Million USD | 104.886% |
| Quantum-Si incorporated | -95.96 Million USD | 113.206% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 117.395% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 165.384% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 113.201% |
| Acasti Pharma Inc. | -12.85 Million USD | 198.592% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 156.426% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 179.39% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 106.948% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | 394.594% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | 201.62% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 142.969% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 132.502% |
| PepGen Inc. | -78.62 Million USD | 116.117% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 142.568% |
| United Therapeutics Corporation | 984.8 Million USD | 98.713% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 156.927% |
| Solid Biosciences Inc. | -96.01 Million USD | 113.198% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 364.47% |
| Immuneering Corporation | -53.47 Million USD | 123.699% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 349.104% |
| Silo Pharma, Inc. | -3.7 Million USD | 442.423% |
| Belite Bio, Inc | -31.63 Million USD | 140.061% |
| XOMA Corporation | -40.83 Million USD | 131.035% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 123.309% |
| Bionomics Limited | -15.49 Billion USD | 100.082% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 115.088% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 143.461% |
| uniQure N.V. | -308.47 Million USD | 104.108% |
| Cassava Sciences, Inc. | -97.21 Million USD | 113.035% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 273.311% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 110.267% |
| Forte Biosciences, Inc. | -31.47 Million USD | 140.259% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | 254.504% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 143.594% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 2468.598% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 148.307% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 176.87% |
| Altimmune, Inc. | -88.44 Million USD | 114.327% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 108.36% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 143.461% |
| Compugen Ltd. | -18.75 Million USD | 167.57% |
| Peak Bio, Inc. | -1259.26 USD | 1006405.29% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 127.519% |
| Benitec Biopharma Inc. | -21.75 Million USD | 158.259% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 103.74% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 115.276% |
| Zura Bio Limited | -60.36 Million USD | 120.994% |
| PolyPid Ltd. | -23.86 Million USD | 153.099% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 180.549% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 115.276% |
| Instil Bio, Inc. | -156.08 Million USD | 108.119% |
| argenx SE | -295.05 Million USD | 104.295% |
| Immunome, Inc. | -106.8 Million USD | 111.865% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 129.821% |
| Verona Pharma plc | -54.36 Million USD | 123.307% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 112.683% |
| Shattuck Labs, Inc. | -87.29 Million USD | 114.516% |
| CervoMed Inc. | -2.17 Million USD | 683.46% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 110.166% |
| Plus Therapeutics, Inc. | -13.31 Million USD | 195.164% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 129.094% |
| Moolec Science SA | -51.78 Million USD | 124.469% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | 73383.587% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 109.379% |
| AnaptysBio, Inc. | -163.61 Million USD | 107.745% |
| Design Therapeutics, Inc. | -66.86 Million USD | 118.952% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 115.565% |
| NeurAxis, Inc. | -14.62 Million USD | 186.636% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 133.451% |
| Lumos Pharma, Inc. | -34.03 Million USD | 137.233% |
| Achilles Therapeutics plc | -69.66 Million USD | 118.19% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 112.683% |
| 180 Life Sciences Corp. | -19.93 Million USD | 163.566% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | -321.166% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 499739.228% |
| Nutriband Inc. | -5.48 Million USD | 331.017% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 112.584% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 126.07% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 116.438% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 137.304% |
| MoonLake Immunotherapeutics | -36 Million USD | 135.193% |
| Palisade Bio, Inc. | -12.3 Million USD | 203.024% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 130.083% |
| Beam Therapeutics Inc. | -132.52 Million USD | 109.562% |
| Neurogene Inc. | -36.31 Million USD | 134.893% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 107.754% |
| AEON Biopharma, Inc. | -52.55 Million USD | 124.111% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 112.911% |
| Sesen Bio, Inc. | -19.88 Million USD | 163.73% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 117.702% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | 201.263% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 102.854% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 111.358% |
| Athira Pharma, Inc. | -117.67 Million USD | 110.769% |
| Vaccinex, Inc. | -20.25 Million USD | 162.575% |
| HCW Biologics Inc. | -24.99 Million USD | 150.7% |
| XOMA Corporation | -40.83 Million USD | 131.035% |
| Nektar Therapeutics | -276.05 Million USD | 104.59% |
| Arvinas, Inc. | -367.3 Million USD | 103.45% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 18922.131% |
| Merus N.V. | -154.93 Million USD | 108.179% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 113.007% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 140.376% |
| Rezolute, Inc. | -68.45 Million USD | 118.51% |
| Clene Inc. | -49.5 Million USD | 125.598% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 182.16% |
| BeyondSpring Inc. | -21.02 Million USD | 160.268% |
| Synlogic, Inc. | -57.28 Million USD | 122.122% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | 206.478% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 217.052% |
| Peak Bio, Inc. | -1259.26 USD | 1006405.29% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 133.911% |
| Krystal Biotech, Inc. | 10.93 Million USD | -15.917% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 108.855% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 103.898% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | 374.347% |
| MannKind Corporation | -11.93 Million USD | 206.148% |
| Ikena Oncology, Inc. | -68.16 Million USD | 118.59% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 160.3% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 113.636% |
| Gossamer Bio, Inc. | -179.81 Million USD | 107.047% |
| CohBar, Inc. | -11.96 Million USD | 205.934% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 149.139% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 142.03% |
| Legend Biotech Corporation | -518.25 Million USD | 102.445% |
| Mural Oncology plc | -207.44 Million USD | 106.109% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 110.21% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 169.285% |
| Disc Medicine, Inc. | -76.42 Million USD | 116.58% |
| Champions Oncology, Inc. | -7.27 Million USD | 274.162% |
| REGENXBIO Inc. | -263.49 Million USD | 104.809% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | 219.4% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 126.675% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 133.362% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 112.651% |
| Vaxart, Inc. | -82.46 Million USD | 115.367% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | -3696.706% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 133.754% |
| Cellectis S.A. | -101.05 Million USD | 112.539% |
| Longeveron Inc. | -21.41 Million USD | 159.179% |
| Repare Therapeutics Inc. | -93.79 Million USD | 113.51% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 102.364% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 117.806% |
| Revolution Medicines, Inc. | -436.36 Million USD | 102.904% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | 292.847% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 141.111% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 118.277% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 119.576% |
| Anixa Biosciences, Inc. | -9.81 Million USD | 229.161% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 99.65% |
| Denali Therapeutics Inc. | -145.22 Million USD | 108.726% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 10637.695% |
| Veru Inc. | -93.15 Million USD | 113.603% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 146.883% |
| Cingulate Inc. | -23.53 Million USD | 153.843% |
| Passage Bio, Inc. | -102.06 Million USD | 112.416% |
| Context Therapeutics Inc. | -23.96 Million USD | 152.879% |
| Exicure, Inc. | -16.91 Million USD | 174.92% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 106.708% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 133.556% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | 294.734% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 106.862% |
| Nuvalent, Inc. | -126.21 Million USD | 110.04% |
| ABVC BioPharma, Inc. | -10.51 Million USD | 220.506% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 114.586% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 141.488% |
| OmniAb, Inc. | -50.61 Million USD | 125.034% |
| Anew Medical, Inc. | 1.34 Million USD | -841.369% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 178.978% |
| Lipocine Inc. | -16.35 Million USD | 177.495% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 119.086% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 119.901% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 130.033% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 126.418% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 163.9% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 102.34% |
| Ocugen, Inc. | -63.07 Million USD | 120.089% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 113.237% |
| Q32 Bio Inc. | -112.96 Million USD | 111.218% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 173.709% |
| Alumis Inc. Common Stock | -154.99 Million USD | 108.176% |
| Equillium, Inc. | -13.33 Million USD | 195.028% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 120.992% |
| Coya Therapeutics, Inc. | -7.98 Million USD | 258.641% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 167.221% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 121.448% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 111.065% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 168.952% |
| Dominari Holdings Inc. | -22.88 Million USD | 155.38% |
| Edesa Biotech, Inc. | -8.37 Million USD | 251.318% |
| vTv Therapeutics Inc. | -20.25 Million USD | 162.578% |
| Bio-Techne Corporation | 168.1 Million USD | 92.462% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 103.599% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | 90.166% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 110.401% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 133.401% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 111.25% |
| Nkarta, Inc. | -117.5 Million USD | 110.785% |
| BioCardia, Inc. | -11.57 Million USD | 209.515% |
| Iterum Therapeutics plc | -38.37 Million USD | 133.025% |